INCAGN01876

Phase 2Small molecule

IIncyte Biosciences International Sàrl

INCAGN01876 is one of 54 small molecule programs targeting Cancer of the Head and Neck. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the Head and NeckActive, not recruiting

GlioblastomaActive, not recruiting

Cancer of the Head and NeckPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

160 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

58 2

Keytruda

Merck & Co.

Phase 3

24 3

Opdivo

Bristol-Myers Squibb

Phase 3

18 4

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Yervoy

11 6

Ceenu

AAzurity Pharmaceuticals

Phase 3

21 7

Antabuse

Teva

Phase 3

5 8

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 9

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Cancer of the Head and Neck

NCT04470024

Q2 2029

Phase 2Active, not recruiting

Glioblastoma

NCT04225039

Clinical

Trials by Indication[1]

Malignancies2 trials

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Completed·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03126110·145 enrolled

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Terminated·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03277352·10 enrolled

Completed·IIncyte Biosciences International Sàrl·Phase 1/2·NCT02697591·100 enrolled

Cancer of the Head and Neck1 trial

A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04470024·19 enrolled

1 more indication

Glioblastoma1 trial

A Phase II Study of the Anti-GITR Agonist INCAGN1876 and the PD-1 Inhibitor INCMGA00012 in Combination With Stereotactic Radiosurgery in Recurrent Glioblastoma

Active, not recruiting·UUniversity of Pennsylvania·Phase 2·NCT04225039·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for INCAGN01876. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCAGN01876 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCAGN01876. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte Biosciences International Sàrl company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIncyte Biosciences International Sàrl

INCAGN01876

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Malignancies2 trials

Head and Neck Squamous Cell Carcinoma1 trial

Biomarker1 trial

Advanced or Metastatic Solid Tumors1 trial

Cancer of the Head and Neck1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News